利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

3 条记录 (耗时 0.023 秒)

    MULTIMODAL SILICA-BASED NANOPARTICLES
    1.
    发明申请
    MULTIMODAL SILICA-BASED NANOPARTICLES 有权
    多元二氧化硅基纳米粒子

    公开(公告)号：US20140248210A1

    公开(公告)日：2014-09-04

    申请号：US14215879

    申请日：2014-03-17

    申请人： CORNELL UNIVERSITY ,  SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH

    发明人： Michelle Bradbury ,  Ulrich Wiesner ,  Oula Penate Medina ,  Andrew Burns ,  Jason Lewis ,  Steven Larson ,  Tom Quinn

    IPC分类号： A61K51/12 ,  A61K47/48 ,  A61K49/00

    CPC分类号： A61K51/1244 ,  A61K49/0002 ,  A61K49/0093 ,  G01N33/54346 ,  G01N33/552 ,  G01N33/574 ,  G01N33/582 ,  G01N33/587 ,  G01N33/60

    摘要： The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo. In order to target a specific cell type, the nanoparticle may further be conjugated to a ligand, which is capable of binding to a cellular component associated with the specific cell type, such as a tumor marker. In one embodiment, a therapeutic agent may be attached to the nanoparticle. To permit the nanoparticle to be detectable by not only optical fluorescence imaging, but also other imaging techniques, such as positron emission tomography (PET), single photon emission computed tomography (SPECT), computerized tomography (CT), bioluminescence imaging, and magnetic resonance imaging (MRI), radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle.

    摘要翻译： 本发明提供一种允许精确检测，表征，监测和治疗诸如癌症的疾病的荧光二氧化硅基纳米颗粒。 纳米颗粒的直径范围包括约0.1nm至约100nm，约0.5nm至约50nm，约1nm至约25nm，约1nm至约15nm，或约1nm至约15nm， 约8nm。 纳米颗粒具有位于纳米颗粒内的荧光化合物，并且具有比游离荧光化合物更大的亮度和荧光量子产率。 纳米颗粒还具有高生物稳定性和生物相容性。 为了促进纳米颗粒的有效尿排泄，可以用有机聚合物如聚（乙二醇）（PEG）包被。 纳米颗粒的小尺寸，二氧化硅基底和有机聚合物涂层在体内施用时使纳米颗粒的毒性最小化。 为了靶向特定的细胞类型，纳米颗粒可进一步与配体结合，该配体能够结合与特定细胞类型相关的细胞成分，例如肿瘤标志物。 在一个实施方案中，治疗剂可以连接到纳米颗粒。 为了允许纳米颗粒不仅可以通过光学荧光成像检测，还可以通过其他成像技术，如正电子发射断层扫描（PET），单光子发射计算机断层扫描（SPECT），计算机断层摄影（CT），生物发光成像和磁共振 成像（MRI），放射性核素/放射性金属或顺磁离子可以与纳米颗粒结合。

    NANOPARTICLE DRUG CONJUGATES
    3.
    发明申请
    NANOPARTICLE DRUG CONJUGATES 审中-公开
    纳米颗粒药物联合用药

    公开(公告)号：US20150343091A1

    公开(公告)日：2015-12-03

    申请号：US14722307

    申请日：2015-05-27

    申请人： Memorial Sloan Kettering Cancer Center ,  Cornell University

    发明人： Barney Yoo ,  Michelle Bradbury ,  Ulrich Wiesner

    IPC分类号： A61K47/48 ,  A61K31/5377 ,  A61K31/506 ,  A61K49/00 ,  A61K51/06

    CPC分类号： A61K31/5377 ,  A61K31/506 ,  A61K47/60 ,  A61K47/65 ,  A61K47/6923 ,  A61K49/0093 ,  A61K51/1244

    摘要： Described herein are nanoparticle drug conjugates (NDCs), which, in certain embodiments, comprise a non-toxic, multi-modality, clinically proven silica-based nanoparticle platform with covalently attached drug molecules/moieties. The nanoparticle drug conjugates (NDCs) demonstrate imaging capability and targeting ligands which efficiently clear through the kidneys. Furthermore, the conjugates incorporate therapeutic agents for cancer detection, prevention, and/or treatment.

    摘要翻译： 本文描述的是纳米颗粒药物共轭物（NDC），其在某些实施方案中包含具有共价连接的药物分子/部分的无毒多模态的临床证实的二氧化硅基纳米颗粒平台。 纳米颗粒药物偶联物（NDCs）显示成像能力和靶向配体，其有效地透过肾脏。 此外，缀合物掺入用于癌症检测，预防和/或治疗的治疗剂。